Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23.
Glucosamine modulates T cell differentiation through downregulating N-linked glycosylation of CD25.
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.
Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.
Treadmill Training or Progressive Strength Training to Improve Walking in People with Multiple Sclerosis? A Randomized Parallel Group Trial.
Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP.
Killer-Cell Immunoglobulin-Like Receptor Expression on Lymphocyte Subsets in Multiple Sclerosis Patients Treated with Interferon-β: Evaluation as Biomarkers for Clinical Response.
Multiple sclerosis: KIR4.1 as an autoantigen in MS-new questions raised.
Prevalence and Impact of Pain in Adults Aging With a Physical Disability: Comparison to a US General Population Sample.
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
[An update on the treatment options for multiple sclerosis].
Sphingolipids in neuroinflammation.
Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis.
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.
[Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)].
Perceptions of caregiver distress, health behaviors, and provider health-promoting communication and their relationship to stress management in MS caregivers.
Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease.
Age-effects in white matter using associated diffusion tensor imaging and magnetization transfer ratio during late childhood and early adolescence.
Ginger Extract Reduces the Expression of IL-17 and IL-23 in the Sera and Central Nervous System of EAE Mice.
Role of TNF in mast cell neuroinflammation and pain.
Remyelinating Oligodendrocyte Precursor Cell miRNAs from the Sfmbt2 Cluster Promote Cell Cycle Arrest and Differentiation.
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.
FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)
Autoimmune disease: A role for new anti-viral therapies?
Pages
« first
‹ previous
…
298
299
300
301
302
303
304
305
306
…
next ›
last »